Literature DB >> 9226508

Genetic engineering: moral aspects and control of practice.

V H Eisenberg1, J G Schenker.   

Abstract

Keywords:  Biomedical and Behavioral Research; Genetics and Reproduction

Mesh：

Year:  1997        PMID： 9226508      PMCID： PMC3454796          DOI： 10.1007/bf02765833

Source DB:  PubMed          Journal:  J Assist Reprod Genet        ISSN： 1058-0468            Impact factor:   3.412


× No keyword cloud information.
  70 in total

Review 1.  Human gene therapy.

Authors:  W F Anderson
Journal:  Science       Date:  1992-05-08       Impact factor: 47.728

2.  Autologous bone marrow transplantation for CML in which retroviral markers are used to discriminate between relapse which arises from systemic disease remaining after preparative therapy versus relapse due to residual leukemia cells in autologous marrow: a pilot trial. The University of Texas M.D. Anderson Cancer Center.

Authors: 
Journal:  Hum Gene Ther       Date:  1991       Impact factor: 5.695

3.  Unsuccessful trial of gene replacement in arginase deficiency.

Authors:  H G Terheggen; A Lowenthal; F Lavinha; J P Colombo; S Rogers
Journal:  Z Kinderheilkd       Date:  1975

4.  Germ-line engineering: a few European voices.

Authors:  A Mauron; J M Thévoz
Journal:  J Med Philos       Date:  1991-12

5.  Overview of regulation of gene therapy in Europe: a current statement including reference to US regulation.

Authors:  O Cohen-Haguenauer
Journal:  Hum Gene Ther       Date:  1995-06       Impact factor: 5.695

6.  Germ-line gene therapy: no place in treatment of genetic disease.

Authors:  D M Danks
Journal:  Hum Gene Ther       Date:  1994-02       Impact factor: 5.695

Review 7.  Regulation of somatic-cell therapy and gene therapy by the food and drug administration.

Authors:  D A Kessler; J P Siegel; P D Noguchi; K C Zoon; K L Feiden; J Woodcock
Journal:  N Engl J Med       Date:  1993-10-14       Impact factor: 91.245

8.  Ethics treaty to target genome implications.

Authors:  D Butler
Journal:  Nature       Date:  1994-09-29       Impact factor: 49.962

9.  Human gene therapy: why draw a line?

Authors:  W F Anderson
Journal:  J Med Philos       Date:  1989-12

10.  The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified.

Authors:  S M Freeman; C N Abboud; K A Whartenby; C H Packman; D S Koeplin; F L Moolten; G N Abraham
Journal:  Cancer Res       Date:  1993-11-01       Impact factor: 12.701
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.